Reviewed Mar 2026 | PubMed sources
Active Market
Germany is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

CJC-1295 vs Tesamorelin: Head-to-Head Comparison

CJC-1295 and tesamorelin are both GHRH analogs but tesamorelin is the only one that is FDA-approved (for HIV-associated lipodystrophy). Tesamorelin has robust clinical trial data showing visceral fat reduction, while CJC-1295 offers convenience with its extended half-life.

Approved Comparison Routing

Approved options in this comparison

A
Tesamorelin

Tesamorelin is currently modeled on this site as an approved treatment path for: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Brand names in the current dataset: Egrifta, Egrifta SV.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Tesamorelin with a provider?

Tesamorelin is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Side-by-Side Comparison

DimensionCJC-1295Tesamorelin
Evidence LevelPhase II trialsPhase III trials, FDA-approved
FDA StatusNot approvedFDA-approved (Egrifta) for HIV lipodystrophy
MechanismModified GHRH with DAC for extended actionGHRH analog (trans-3-hexenoic acid modification)
Primary UseGH optimization, anti-aging, body compositionVisceral fat reduction in HIV lipodystrophy
Half-Life~6-8 days (DAC)~26-38 minutes
Side EffectsInjection site reactions, water retentionInjection site reactions, arthralgia, peripheral edema
CostModerate (research peptide pricing)Very high (branded pharmaceutical)
Evidence Level
CJC-1295
Phase II trials
Tesamorelin
Phase III trials, FDA-approved
FDA Status
CJC-1295
Not approved
Tesamorelin
FDA-approved (Egrifta) for HIV lipodystrophy
Mechanism
CJC-1295
Modified GHRH with DAC for extended action
Tesamorelin
GHRH analog (trans-3-hexenoic acid modification)
Primary Use
CJC-1295
GH optimization, anti-aging, body composition
Tesamorelin
Visceral fat reduction in HIV lipodystrophy
Half-Life
CJC-1295
~6-8 days (DAC)
Tesamorelin
~26-38 minutes
Side Effects
CJC-1295
Injection site reactions, water retention
Tesamorelin
Injection site reactions, arthralgia, peripheral edema
Cost
CJC-1295
Moderate (research peptide pricing)
Tesamorelin
Very high (branded pharmaceutical)

Peptide Overviews

CJC-1295

BHuman Studies

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Available in two forms: with and without Drug Affinity Complex (DAC), which extends its half-life.

Growth Hormone SecretagoguesNot Approved
View full CJC-1295 profile →

Tesamorelin

AFDA Approved

Tesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Growth Hormone SecretagoguesFDA Approved
View full Tesamorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

CJC-1295 vs Tesamorelin: FAQ